

Overcoming Chemoresistance in Cancer: Identifying Biomarkers and Novel Targets

Guest Editors:

Dr. Annapina Russo

Department of Pharmacy,
University of Naples “Federico II”,
80131 Naples, Italy

Dr. Giulia Russo

Department of Pharmacy,
University of Naples “Federico II”,
80131 Naples, Italy

Dr. Annalisa Pecoraro

Department of Pharmacy,
University of Naples “Federico II”,
80131 Naples, Italy

Deadline for manuscript
submissions:

1 March 2025

Message from the Guest Editors

Dear Colleagues,

The development of chemoresistance remains the main obstacle in the successful treatment of cancer. There is no doubt that a great deal of work has been done in the last few years to increase our understanding of the mechanisms behind the development of drug resistance in cancer. However, the identification of new targets is crucial for the development of personalized therapeutic strategies aiming to overcome chemoresistance.

In this Special Issue of *Cancers*, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the identification of novel molecular mechanisms of chemoresistance; the discovery of novel molecular biomarkers to allow cancer patient stratification and personalized treatment; the discovery of new drug targets; and the development of novel combined treatments targeting multiple signaling pathways.

We look forward to receiving your contributions.


Dr. Annapina Russo

Dr. Giulia Russo

Dr. Annalisa Pecoraro

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)